P480: Ustekinumab Dose Intensification Is Effective in One-Third of Asian Inflammatory Bowel Disease Patients, Results From A Tertiary Inflammatory Bowel Disease Centre.ECCO’23 CopenhagenYear: 2023
Authors: Lim, C.T.(1)*;Tay, S.W.(1);Lim, G.H.(2);Salazar, E.(1);Ong, W.C.(3);Chan, W.P.W.(1);Tan, M.T.K.(1);
(1)Singapore General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(2)Singapore General Hospital, Health Services Research Unit, Singapore, Singapore;(3)Singapore General Hospital, Department of Pharmacy, Singapore, Singapore;
P481: Visceral fat to skeletal muscle area ratio predicts for Ustekinumab loss of response.ECCO’23 CopenhagenYear: 2023
Authors: Tan, Z.(1)*;Chin, A.(2);Welman, C.J.(3,4);Thin, L.W.Y.(1,5);
(1)Fiona Stanley Hospital, Gastroenterology, Murdoch, Australia;(2)Royal Perth Hospital, Gastroenterology, Perth, Australia;(3)Fiona Stanley Hospital, Medical Imaging, Murdoch, Australia;(4)Royal Perth Hospital, Radiology, Perth, Australia;(5)University of Western Australia, Internal Medicine, Perth, Australia;
P483: Golimumab response in Ulcerative Colitis as early as week 2: What can we take from this?ECCO’23 CopenhagenYear: 2023
Authors: Kumar, L.(1)*;O'Morain, N.(1);Sheridan, J.(1);Coe, C.(1);Egan, C.(1);Jones, F.(1);Cullen, G.(1);Doran, P.(2);Leyden, J.(3);Galligan, M.(2);McCarthy, J.(4);O'Toole, A.(5);Kevans, D.(6);Egan, L.(7);Doherty, G.(1);
(1)St. Vincent's University Hospital, Gastroenterology, Dublin, Ireland;(2)University College Dublin, Clinical Research, Dublin, Ireland;(3)Mater Misericordiae University Hospital, Gastroenterology, Dublin, Ireland;(4)Mercy University Hospital, Gastroenterology, Cork, Ireland;(5)Beaumont Hospital, Gastroenterology, Dublin, Ireland;(6)St. James's Hospital, Gastroenterology, Dublin, Ireland;(7)University Hospital Galway, Gastroenterology, Galway, Ireland;Investigator Network for Inflammatory Bowel Disease Therapy in Ireland (INITIative)
P484: Inflammatory Bowel Disease exercise and diet habits (IBDeat) study: chronic metabolic disease risk factors among IBD patients in New ZealandECCO’23 CopenhagenYear: 2023
Authors: Yap, J.(1)*;Wall, C.(2);Meredith-Jones, K.(1);Iosua, E.(1);Osborne, H.(1);Schultz, M.(1);
(1)University of Otago, Medicine, Dunedin, New Zealand;(2)University of Otago, Medicine, Christchurch, New Zealand;
P486: Improving enhanced recovery after surgery (ERAS): the effect of a patient-centred mobile application on patient participation in colorectal surgeryECCO’23 CopenhagenYear: 2023
Authors: Van Der Storm, S.(1)*;Jansen, M.(1);Marsman, H.A.(2);Molly, G.P.(3);Consten, E.C.(4);Groot, L.M.(4);Boer, F.C.(5);Corver, M.(5);Oosterling, S.J.(6); Tuynman, J.B.(7);Bemelman, W.A.(1);Buskens, C.J.(1);Schijven, M.P.(1);
(1)Amsterdam University Medical Center- location AMC, Surgery, Amsterdam, The Netherlands;(2)OLVG Hospital, Surgery, Amsterdam, The Netherlands;(3)OLVG, Surgery, Amsterdam, The Netherlands;(4)Meander Medical Center, Surgery, Amersfoort, The Netherlands;(5)Zaans Medical Center, Surgery, Zaandam, The Netherlands;(6)Spaarne Gasthuis Hospital, Surgery, Hoofddorp, The Netherlands;(7)Amsterdam University Medical Center- location VUmc, Surgery, Amsterdam, The Netherlands;
P488: Switch from intravenous to subcutaneous infliximab in patients with Inflammatory Bowel Disease: efficacy, safety and patients' acceptanceECCO’23 CopenhagenYear: 2023
Authors: Caballol Oliva, B.(1)*;Fernàndez-Clotet, A.(2);Panés, J.(2);Masamunt, M.C.(2);Gallego, M.(2);Barastegui, R.(2);Vara, A.(2);Giner, À.(2);Ricart, E.(2);Ordás, I.(2);
(1)Hospital Clínic i Provincial- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and CIBEREHD, Gastroenterology, Barcelona, Spain;(2)Hospital Clínic i Provincial- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS- and CIBEREHD, Gastroenterology, Barcelona, Spain;
P490: Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trialsECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Peyrin-Biroulet, L.(2,3);Panés, J.(4);Regueiro, M.(5);Kotze, P.G.(6);Charabaty, A.(7);Goetsch, M.(8);Shan, K.(9);Wu, J.(10);McDonnell, A.(11);Woolcott, J.(12);Danese, S.(13);
(1)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(2)University of Lorraine- Inserm- NGERE, Gastroenterology, Nancy, France;(3)Groupe Hospitalier privé Ambroise Paré - Hartmann, Paris IBD Center, Neuilly sur Seine, France;(4)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(5)Cleveland Clinic, Department of Digestive Disease and Surgery Institute, Cleveland- Ohio, United States;(6)Pontifícia Universidade Católica do Paraná PUCPR, Colorectal Surgery Unit, Curitiba, Brazil;(7)Johns Hopkins School of Medicine, Gastroenterology, Washington- District of Columbia, United States;(8)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(9)Pfizer- Inc, Biostatistics, New York- New York, United States;(10)Pfizer- Inc, Biostatistics, Groton- Connecticut, United States;(11)Pfizer Ltd, Safety Risk, Walton Oaks- Scurry, United Kingdom;(12)Pfizer Inc, Global Medical Affairs- Gastroenterology, Collegeville- Pennsylvania, United States;(13)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;
P491: Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Colombel, J.F.(1)*;Irving, P.(2);Rieder, F.(3);Panaccione, R.(4);Schwartz, D.(5);Hayashi, R.(6);Zhu, X.(7);Lacerda, A.P.(8);Dubcenco, E.(8);Marced, E.(8);Hecht, P.(8);Feng, T.(8);Berg, S.(8);Reinisch, W.(9);
(1)Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States;(2)Guy's and St Thomas' NHS Foundation Trust, IBD Centre, London, United Kingdom;(3)Digestive Diseases and Surgery Institute- Cleveland Clinic, Department of Gastroenterology- Hepatology- & Nutrition, Cleveland, United States;(4)University of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada;(5)Vanderbilt University Medical Center, Department of Gastroenterology and Hepatology, Nashville, United States;(6)Hiroshima University Hospital, Department of Endoscopy, Hiroshima, Japan;(7)First Affiliated Hospital of Nanchang University, Departments of Gastroenterology and Hepatology, Nanchang, China;(8)AbbVie Inc., Research and Development, North Chicago, United States;(9)Medical University of Vienna, Department of Internal Medicine, Vienna, Austria;
P492: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC studyECCO’23 CopenhagenYear: 2023
Authors: Sands, B.E.(1)*;Hanauer, S.B.(2);Colombel, J.F.(3);Sandborn, W.(4);Schreiber, S.(5);Danese, S.(6);Klopocka, M.(7);Kulynych, R.(8);Kierkus, J.(9);Soltysiak, A.(10);Smolinski, P.(11);Gonciarz, M.(12);Sreckovic, S.(13);Valuyskikh, E.(14);Horynski, M.(15);Gasbarrini, A.(16);Kim, S.(17);Bae, Y.(17);Lee, S.(17);Lee, J.H.(17);Lee, J.(17);Lee, S.J.(18);Lee, S.G.(18);Kim, J.M.(18);
(1)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)Northwestern University/ Feinberg School of Medicine, Gastroenterology and Hepatology, Chicago- IL, United States;(3)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(4)University of California San Diego, Gastroenterology, La Jolla, United States;(5)University Hospital Schleswig Holstein, Medicine I, Kiel, Germany;(6)IRCCS San Raffaele Hospital, Gastroenterology, Milan, Italy;(7)Nicolaus Copernicus University- Collegium Medicum in Bydgoszcz, Gastroenterology and Nutrition Disorders, Bydgoszcz, Poland;(8)Zaporizhzhia regional clinical hospital, Gastroenterology and Endoscopy, Zaporizhzhia, Ukraine;(9)The Children Memorial Health Institute, Gastroenterology- Hepatology- Feeding Disorders and Pediatrics, Warsaw, Poland;(10)Centrum Medyczne Lukamed Joanna Łuka, Centrum Medyczne Lukamed Joanna Łuka, Chojnice, Poland;(11)EuroMediCare Szpital Specjalistyczny, Gastroenterology Clinical Trials, Wroclaw, Poland;(12)Military Institute of Medicine - National Research Institute, Gastroenterology and Internal Diseases, Warsaw, Poland;(13)Clinical university hospital Zvezdara, Gastroenterology and hepatology, Belgrade, Serbia;(14)LLC Novosibirskiy Gastrocenter, Clinical Research, Novosibirsk, Russian Federation;(15)Endoskopia sp. Z o.o, Gastroentrology, Sopot, Poland;(16)Dipartimento Medicina e Chirurgia Traslazionale, Dipartimento Medicina e Chirurgia Traslazionale, Roma, Italy;(17)Celltrion- Inc., Medical Science Division, Incheon, Korea- Republic Of;(18)Celltrion- Inc., Data Science Institute, Incheon, Korea- Republic Of;CT-P13
P493: QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Peyrin-Biroulet, L.(1)*;Rubin, D.(2);Lichtenstein, G.(3);Shipitofsky, N.(4);Huang, K.H.(4);Germinaro, M.(4);Wilson, R.(5);Zhang, H.(5);DuVall, G.A.(6);Cao, Q.(7);Allegretti, J.(8);Feagan, B.(9);Hisamatsu, T.(10);Panés, J.(11);Dignass, A.(12);Bressler, B.(13);Sands, B.(14);
(1)Nancy University Hospital, Gastroenterology, Nancy, France;(2)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(3)Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania, Department of Medicine- Division of Gastroenterology, Philadelphia, United States;(4)Janssen Research & Development- LLC, Immunology, Spring House, United States;(5)Janssen Research & Development- LLC, Biostatistics, Spring House, United States;(6)Tyler Research Institute- LLC, Gastroenterology, Tyler, United States;(7)Zhejiang University School of Medicine, School of Medicine, Hangzhou, China;(8)Brigham and Women's Hospital Crohn's and Colitis Center, Gastroenterology- Hepatology and Endoscopy, Boston, United States;(9)Alimentiv Inc, Gastroenterology, London, Canada;(10)Kyorin University, Gastroenterology and Hepatology, Tokyo, Japan;(11)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(12)Agaplesion Markus Hospital, Department of Medicine, Frankfurt, Germany;(13)University of British Columbia, Division of Gastroenterology, Vancouver, Canada;(14)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;QUASAR Investigators
P494: Impact of early optimization of ustekinumab on mid-term targets in severe Crohn's disease: THE MUST studyECCO’23 CopenhagenYear: 2023
Authors: Abdelmoula, A.(1)*;Chateau, T.(2);Hupe, M.(2);Boschetti, G.(3);Roblin, X.(4);Nancey, S.(3);Mathieu, N.(2);
(1)Grenoble Alps University Hospital, Hepato-gastroenterology and digestive oncology department-, Grenoble, France;(2)Grenoble Alps University Hospital, Hepato-gastroenterology and digestive oncology department, Grenoble, France;(3)Lyon Sud University Hospital- Pierre Bénite, Gastro Enterology Department-, Lyon, France;(4)St Etienne University Hospital- St Priest en Jarez, Gastro Enterology Department, St Etienne, France;
P495: Vedolizumab trough concentrations and histological remission in Ulcerative Colitis: Results from the LOVE-UC studyECCO’23 CopenhagenYear: 2023
Authors: Hanzel, J.(1)*;Baert, F.(2);Löwenberg, M.(3);Ferrante, M.(4);Bossuyt, P.(5);Hoentjen, F.(6);Franchimont, D.(7);Palatka, K.(8);Peeters, H.(9);Mookhoek, A.(10);de Hertogh, G.(11);Clasquin, E.(3);Vermeire, S.(4);D'Haens, G.(3);
(1)University Medical Centre Ljubiljana, Department of Gastroenterology, Ljubljana, Slovenia;(2)AZ Delta, Department of Gastroenterology, Roeselare, Belgium;(3)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(4)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)Imelda General Hospital, Imelda Clinical Research Centre, Bonheiden, Belgium;(6)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;(7)Erasme Hospital, Department of Gastroenterology, Brussels, Belgium;(8)University of Debrecen, Division of Gastroenterology- Department of Internal Medicine, Debrecen, Hungary;(9)AZ Sint Lucas, Department of Gastroenterology, Gent, Belgium;(10)Bern University, Institute of Pathology, Bern, Switzerland;(11)University Hospitals Leuven, Department of Pathology, Leuven, Belgium;
P496: Antenatal thiopurine exposure in women with IBD is associated with intrahepatic cholestasis of pregnancyECCO’23 CopenhagenYear: 2023
Authors: Rosiou, K.(1)*;Broglio, G.(1,2);Lever, G.(1);Chiu, C.M.(1);Stocker, L.J.(3);Chipeta, H.(3);Glanville, T.(3);Selinger, C.P.(1);
(1)Leeds Teaching Hospitals, Leeds Gastroenterology Institute, Leeds, United Kingdom;(2)IRCCS Fondazione Policlinico San Matteo, Internal Medicine, Pavia, Italy;(3)Leeds Teaching Hospitals, Department of Obstetrics, Leeds, United Kingdom;
P497: Is early bowel resection better than medical therapy for ileocolonic Crohn's disease? A systematic review and meta-analysisECCO’23 CopenhagenYear: 2023
Authors: Husnoo, N.(1);Gana, T.(2);Hague, A.G.(2);Khan, Z.(2);Morgan, J.L.(1);Wyld, L.(1);Brown, S.R.(2)*;
(1)University of Sheffield, Oncology and Metabolism, Sheffield, United Kingdom;(2)Sheffield Teaching Hospitals NHS Foundation Trust, General Surgery, Sheffield, United Kingdom;
P498: Ustekinumab Real World Evidence Study (UndieS): study design with information about positioning and the choice of ustekinumabECCO’23 CopenhagenYear: 2023
Authors: Young, D.(1,2);Booker, C.(1);Samaan, M.(3);Limdi, J.(4,5);Kok, K.(6);Donovan, F.(7);Hart, A.(8);Smith, M.(9);Bodger, K.(10);Batchelor, J.(2);Cummings, F.(1,2)*;
(1)University Hospital Southampton NHS Foundation Trust, Department of Gastroenterology, Southampton, United Kingdom;(2)University of Southampton, Faculty of Medicine, Southampton, United Kingdom;(3)Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(4)Northern Care Alliance NHS Foundation Trust NE Sector, Department of Gastroenterology, Manchester, United Kingdom;(5)University of Manchester, School of Medical Sciences, Manchester, United Kingdom;(6)Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom;(7)St George's University Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(8)St Marks Hospital and Academic Institute, Department of Gastroenterology, London, United Kingdom;(9)University Hospitals Sussex NHS Foundation Trust, Department of Gastroenterology, Brighton, United Kingdom;(10)University of Liverpool, Department of Health Data Science, Liverpool, United Kingdom;On behalf of the UndieS studygroup.
P499: Exclusive enteral nutrition induces transmural healing in adults with active Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Chu, M.(1)*;Day, A.(1);Mathias, R.(1);Direen, T.(2);Broad, L.(3);Lynch, K.(4);Bryant, R.(1);
(1)The Queen Elizabeth Hospital, The Department of Gastroenterology and Hepatology, Adelaide, Australia;(2)The Queen Elizabeth Hospital, Department of Nutrition and Dietetics, Adelaide, Australia;(3)Royal Adelaide Hospital, Department of Nutrition and Dietetics, Adelaide, Australia;(4)Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, Australia;
